**Prevalence of Erectile Dysfunction in Male Cancer Survivors: a Systematic Review and Meta-Analysis of Cross-Sectional Studies**

Damiano Pizzol1±, MD, Tao Xiao2±, PhD, Lee Smith3\*, PhD, Guillermo F. López Sánchez4, PhD, Andrea Garolla5, MD, Christopher Parris6, PhD, Yvonne Barnett7, PhD, Petre Cristian Ilie8, MD, Pinar Soysal9, MD, Jae II Shin10, MD, Mark A Tully11, PhD, Lin Yang12, PhD, Nicola Veronese13, MD, Igor Grabovac14, MD

1. Italian Agency for Development Cooperation - Khartoum, Sudan

2. College of Mathematics and Statistics, Shenzhen University, Shenzhen 518060, China

3. The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK, CB1 1PT

4. Faculty of Sport Sciences, University of Murcia, Spain.

5. Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padova, Padova, Italy

6. Biomedical Research Group, Faculty of Science and Engineering, Anglia Ruskin University, Cambridge, UK

7. Anglia Ruskin University, Cambridge, UK

8. The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King’s Lynn PE30 4ET, UK

9. Department of Geriatric Medicine, Bezmialem Vakif University, Istanbul 34093, Turkey

10. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea.

11. School of Health Sciences, Institute of Mental Health Sciences, Ulster University, Newtownabbey BT15 1ED, Northern Ireland

12. Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Holy Cross Centre T5J 3E4, Canada

13. Neuroscience Institute, Aging Branch, National Research Council, Padua 35122, Italy

14. Department of Social and Preventive Medicine, Centre for Public Health, Medical University of Vienna, Vienna, Austria

± Authors contributed equally

\*Corresponding author: Dr Lee Smith, The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK, CB1 1PT; [lee.smith@anglia.ac.uk](mailto:lee.smith@anglia.ac.uk)

# Abstract

**Background:** Normal sexual function is one of the most improtant aspects of well being and quality of life. In male cancer survivors normal sexual function may be problematic and normal erectile function may be compromised due to issues associated with cancer disease and treatment. However, the prevalence of erectile dysfunction (ED) in male cancer survivors across cancer types has not been systematically analysed.

**Aim:** We conducted a systematic review and meta-analysis to estimate the prevalence of ED in all types of cancer and identify characteristics associated with ED in cancer survivors.

**Design and Setting:** Systematic review and meta-analysis of cross-sectional studies.

**Method:** We searched four electronic databases – Medline Cinhal, PsychInfo and Embase – targeting reports published until 1st of February 2020. All retrospective or prospective studies reporting the prevalence of ED in male patients with cancer and using a validated tool for the detection of ED (e.g. the International Index of Erectile Function, IIEF-5) were included in this review. Random-effects meta-analysis (MA) model was used to pool the prevalence of ED as absolute estimates at three different stages (i.e., healthy, at diagnosis, and after treatment stages). A univariate MA regression including the three-level group variable as the only independent variable was used to assess the difference of prevalence of ED across the three groups. Further MA were conducted for studies involving patients at diagnosis and after treatment and statistical inferences were made with setting for multiple testing controlling for false discovery rate less than 0.05. Graphical comparisons of the prevalence of ED across these two stages of cancer treatment were given by a classic forest plot.

**Results:** 1301 studies were assessed for inclusion. Of those, 141 were potentially eligible and subsequently scrutinizedscrutinised in full text. We included 43 studies with a total of 19,329 participants. Overall the pooled data of the included studies showed an ED prevalence of 40.72% (95%CI: 31.80-50.29) in cancer patients, with prevalence of 28.60% (95%CI: 12.10%-53.83%) at time of diagnosis and 42.70% (95%CI: 32.97%-53.03%) after treatment, with significant difference between these two stages and across cancer locations, controlling for false discovery rate less than 0.05.

**Conclusion:** ED is particularly high in male cancer survivors and was found to be associated with cancer treatment, cancer site, and age.

**Keywords:** Erectile Dysfunction; Male Cancer; Systematic Review; Meta-Analysis.

**How this fits in**

* In male cancer survivors, normal sexual function may be disturbed due to occurrence of erectile dysfunction.
* Our systematic literature review and meta-analysis reported a prevalence of 40.72% of erectile dysfunction in cancer survivors, with prevalence being somewhat higher in studies that focused on reporting prevalence after cancer treatment with 42.70%.
* The reasons of high occurrence of erectile dysfunction in male cancer survivors is multimodal and it includes a variety of factors including psychological and physical ones.
* Clinicians should be aware that erectile dysfunction has a large effect on the quality of life and mental health of male cancer survivors.

**Introduction**

Cancers located in the pelvic region represent more than a quarter of all newly diagnosed cancers worldwide in men.1 This localisation of cancer has also been associated with long term severe sexual dysfunction in at least half of all patients.2 Erectile dysfunction (ED), the inability to obtain or maintain an erection that allows for sexual intercourse, is one of the most distressing consequences of cancer diagnosis and treatment in men.3

Erectile dysfunction has a complex aetiology influenced by cancer in both direct and indirect ways. Men diagnosed with prostate cancer, the second most common type of cancer (except for non-melanoma skin cancer) in men,1 are expected to have the same risk factors (cardiovascular disease and metabolic disorders) for ED when compared with cancer-free age matched men. However, in men with prostate cancer, risks for ED are increased given higher incidence of lower urinary tract symptoms and psychological distress.4,5 Indirect pathways, mostly associated with cancer treatment modalities (surgery, radio- and chemotherapy and hormone treatment) seem to be the most common cause.6,7

Moreover, few men are able to achieve normal erection following pelvic surgery, with studies noting that even in men with excellent baseline erections, less than one quarter retained or recovered the erection quality prior to treatment. Pelvic surgeries most associated with ED are radical prostatectomy, radical cystectomy and low anterior or abdominoperineal resections.8 Furthermore, the results from a 12 year follow up study showed that 84% and 80% of men with prostate cancer who had radical prostatectomy or were under active surveillance reported ED, respectively, compared to 43% in the matched control group.9 Similar results have been reported for men who had treatment for other types of pelvic cancer such as anal, rectal or bladder cancer.10-15 However, it is noteworthy that ED is not only prevalent in men with pelvic cancers but may also be the result of intensive chemotherapy or radiotherapy, causing hypogonadism or pelvic nerve damage. Studies have shown ED also after lung cancer, haematological malignancies and head and neck tumours.16-18

Sexuality and intimacy are important aspects of quality of life and may also reduce some of the psychosocial distress associated with the cancer diagnosis. In this light it has been reported that maintaining a normal sexual function in men with cancer can be important to help relieve suffering.19,20 Given the growing incidence of cancer globally and the new therapeutic modalities that are prolonging life expectancy in cancer survivors, questions of quality of life post-diagnosis and treatment are more and more relevant. However, studies focusing on ED in cancer survivors are rare, and mostly focused on cancer localisations in the pelvic region, making prevalence estimates of ED in cancer survivors rare. Providing pooled estimates of the prevalence of ED as well as its associations should provide important information not only on the scale of the issue but also help clinicians working with cancer survivors to easily identify patients who are at risk of ED but also to provide comprehensive cancer care that is associated long-term quality of life of cancer survivors.

Therefore, the aim of this systematic review and meta-analysis (MA) was to examine the available studies and provide pool estimates for ED prevalence in relation to all cancer sites and identify characteristics associated with ED in cancer survivors. To our knowledge this is the first study of its kind.

**Material and methods**

Search strategy

We searched four electronic databases – Medline Cinhal, PsychInfo and Embase – targeting reports published until 1st of February 2020. The search strategy included terms reported in **Supplementary Table 1.**

The references of retrieved articles together with the proceedings of relevant conferences were hand-searched in order to identify other potentially eligible studies for inclusion in the analysis missed by the initial search or any unpublished data.

The literature search, assessment of inclusion and exclusion criteria, quality of studies and extraction of data were independently undertaken and veriﬁed by two investigators (DP, TX). The results were then compared and, in case of discrepancies, a consensus was reached with the involvement of a third investigator (LS). There was no language restriction.

Type of studies, inclusion and exclusion criteria

All retrospective or prospective studies reporting the prevalence of ED in male patients with cancer and using a validated tool for the detection of ED (e.g. the International Index of Erectile Function, IIEF-5) were included in this review. We excluded studies that didn’t meet the inclusion criteria.

Types of outcome measures

All outcomes were deﬁned prior to the literature search. The primary outcome was the prevalence of ED across cancer treatment relevant stages (i.e., healthy, at diagnosis, and after treatment stages).

Data extraction and statistical analyses

For all included studies, we generated descriptive tables for population and study characteristics. We recorded the ﬁrst author, publication year, country of the investigators, sample size, age, method of assessment of ED and cancer type and site. Furthermore, number of ED patients among case and control groups, BMI, hormonal levels, smoking, hypertension, diabetes, dyslipidemia and cardiovascular diseases were recorded. All statistical analyses based on these data were performed using R (version 3.6.1).21

For the included studies at the three different stages (i.e., healthy, at diagnosis, and after treatment stages), random-effects meta-analysis model with the between-study heterogeneity parameter estimated by DerSimonian-Laird (DL) method 22 was used to pool the prevalence of ED as absolute estimates (in %) with their 95% confidence intervals (CIs) for each of three stages of patients. A univariate MA regression including the three-level group variable for healthy/diagnosis/treatment stages as the only independent variable was used to assess the difference of prevalence of ED across the three stages. A scatter plot with point and confidence interval estimates of prevalence of ED across three different groups of patients are illustrated. Publication bias was assessed by a visual inspection of funnel plots and calculating the Egger bias test.23 In case of publication bias (p<0.10), we planned to apply the trim and fill-analysis 24 for overcoming this bias.

Further MA were conducted for the 40 studies only involving patients at diagnosis and after treatment (i.e., excluding healthy control). Graphical comparisons of the prevalence of ED across these two stages of cancer treatment were given by a classic forest plot. Heterogeneity across these 40 studies involving the two cancer treatment stages was assessed by the I2 metric and taking as measure of high heterogeneity an I2 >50% or p<0.05 for testing the Chi2-distributed Q statistic for between-studies heterogeneity (a high value of Q would result in a high value of I2 since I2 = (Q-K+1)/Q where K is the number of studies).25 In case of high heterogeneity of the prevalence of ED and having at least 10 studies for the outcome, we used, as possible predictors for MA regression analyses: stage, continent, mean age, range of age, method of ED assessment, cancer site, standard deviation of age, proportion of patients underwent radiotherapy, proportion of patients with diabetes, proportion of patients underwent chemotherapy. The plots of study count distribution for each of the above moderators across their observed values are given. Univariate MA regression model for each moderator was fit. The stage predictor as well as the significant moderators screened out by these univariate MA regression analyses were used as potential predictors to fit a multiple MA regression with manual variable selection procedure applied. The conclusions by the final multiple MA regression model were drawn with multiple testing concern by controlling for false discovery rate (FDR).26 Back-transformed estimated prevalence values of ED with 95% C.I. for studies with different levels of predictor variables in the final multiple MA regression model were given.

For all MA regression, we applied the logit transformation to the observed prevalence across primary studies to make the transformed prevalence follow a normal distribution, and the MA regression analysis is based on the transformed scale.

*Assessment of study quality*

Study quality was assessed by two investigators (DP, LS) using the Newcastle-Ottawa Scale (NOS).27,28 This scale has been adapted from the Newcastle-Ottawa Quality Assessment Scale for cohort studies to perform a quality assessment of cross-sectional studies for the systematic review.27,28 A third reviewer was available for mediation (NV). The NOS assigns a maximum of 9 points based on three quality parameters: selection, comparability, and outcome.

**Results**

The electronic search yielded, after de-duplication, 1301 studies that were assessed for inclusion in the review. Of those, 141 were potentially eligible and subsequently scrutinised in full text (Supplementary Figure 1).

Excluded studies

Amongst the relevant studies, 98 failed to meet the inclusion criteria and were excluded from this overview. Of these, 37 used no validated tools for ED assessment, 36 had no useful data on ED prevalence, 18 were longitudinal studies, 4 had no data on the association between ED and cancer and 3 were double publications.

*Included studies*

The 43 studies, 36 prospective and 7 retrospective, included a total of 19,329 participants. The majority of the studies (n=25) were conducted in Europe, 6 in North America, 6 in Asia, 5 in Middle East and 1 in Oceania. The most affected sites were: prostate and rectum (12 studies each), testis (6), haematological (5), multiple sites (3), colorectal (2), and penis, colon and anus (1 each).

The median quality of the studies was 4.97 (range: 3-7), indicating an overall good quality of the studies, according to the NOS (**Supplementary Table 2**). In particular, the majority of the studies (18) scored 5, followed by 11 studies with 4. Only 3 studies scored 3 while 6 and 5 studies scored 6 and 7 respectively.

Meta-analysis on Prevalence of ED across three stages (i.e., healthy, at diagnosis, and after treatment stages)

Distribution of study counts and the corresponding pooled prevalence of ED at the three different stages are given in Table 1. The pooled prevalence of ED at the stage of after treatment was significantly different from that of healthy control by the univariate MA regression analysis with dummy variables for *stage* (p = 0.0322).

To compare prevalence of ED among patients in the two cancer treatment stages with that of healthy control people, we also illustrate the pooled prevalence of these three groups of people in Figure 1, with the pooled prevalence of ED given in red square and the corresponding CI given in red extending line (blue circles are centered at the prevalence of ED reported in each of the included primary studies with circle size proportional to sample size of each primary study).

Small study effect (including publication bias) was not found among the included studies and the trim and fill analysis did not modify our results. Figure 2 shows the funnel plot, with non-significant Egger’s test result for funnel plot asymmetry (p = 0.4418).

Meta-analysis on Prevalence of ED across the two cancer treatment stages (i.e., at diagnosis, and after treatment stages)

Pooling the data of the 40 studies of cancer patients only (i.e., excluding 3 studies of healthy controls), we found an overall prevalence of 40.72% (95%CI: 31.80-50.29) with a high degree of overall heterogeneity (I2=98%; p<0.0001). Figure 3 shows the prevalence of ED among cancer patients.

To locate the potential predictors that account for the very high heterogeneity of prevalence of ED among all the primary studies involving cancer patients in the two treatment stages, MA regression analyses were conducted with ten predictors used. Distribution plots of Study Count for each of the 10 possible predictors are given in Supplementary Figure 2. Study counts of these 10 possible predictors for the ED prevalence among cancer patients and p-value for continuous predictor (or smallest p-value for the dummy variables of categorical predictor) in the univariate MA regression analysis are given in Table 2. The results by the univariate MA regression showed that the following mean age and cancer site are variables that are significantly associated with the ED prevalence.

After a manual variable selection accounting for the multicollinearities of the predictors, a parsimonious MA regression model was built to predict the highly heterogeneous ED prevalence. Regression coefficient estimates of this prediction model are given in Table 3. This model only included two predictors, *Stage* and *Cancer Site*. Since both of them are categorical variables, dummy variables are created to represent them. The reference level for *Stage* is selected as “at diagnosis”, and the reference level for Cancer Site is selected as “prostate” since prostate cancer has the highest count (12) in the collected primary study data (this count is same as the rectum cancer) and prostate cancer is a common cancer in urology. Both predictors are significant controlling for false discovery rate less than 5% in this MA regression model indicating that the ED prevalence estimates reported by primary studies are significantly associated with factors of stage and cancer site. The interpretations of those significant regression coefficients are given as follows: study-reported odds of ED at after-treatment stage is estimated to be 2.4823 (i.e., exponential of 0.9092) times of that at diagnosis stage controlling for other covariates (95% C.I.: 1.3054 to 4.7204; adjusted p-value controlling for FDR: 0.0204); study-reported odds of ED for patients with colon cancer is estimated to be 0.23 (i.e., exponential of -1.4697) times of that for patients with prostate cancer controlling for other covariates (95% C.I.: 0.0697 to 0.7587; adjusted p-value controlling for FDR: 0.0434); study-reported odds of ED for patients with lymphoma cancer is estimated to be 0.2530 (i.e., exponential of -1.3744) times of that for patients with prostate cancer controlling for other covariates (95% C.I.: 0.0756 to 0.8470; adjusted p-value controlling for FDR: 0.0473); study-reported odds of ED for patients with multiple cancers is estimated to be 0.1041 (i.e., exponential of -2.2625) times of that for patients with prostate cancer controlling for other covariates (95% C.I.: 0.0419 to 0.2586; adjusted p-value controlling for FDR: < .0001); study-reported odds of ED for patients with penis cancer is estimated to be 0.1725 (i.e., exponential of -1.7574) times of that for patients with prostate cancer controlling for other covariates (95% C.I.: 0.0394 to 0.7553; adjusted p-value adjusted p-value controlling for FDR: 0.0433); study-reported odds of ED for patients with testis cancer is estimated to be 0.1353 (i.e., exponential of 2.0001) times of that for patients with prostate cancer controlling for other covariates (95% C.I.: 0.0730 to 0.2508; adjusted p-value controlling for FDR: < .0001).

The R2 value of this MA regression is as high as 75.70%, indicating that this MA regression model already accounts for 75.70% heterogeneity of the ED prevalence reported by the 40 studies involving studies of cancer patients. The back-transformed estimated prevalence values of ED for studies with patients of different cancers at the two stages by this MA regression are given in Table 4.

**Discussion**

## Summary

In our systematic review our search yielded 1301 individual studies, out of which 43 studies with overall 19,329 participants were included in the analysis. Our study provides pooled estimates for ED in cancer survivors across all cancer sites providing synthesized data of this kind for the first time. Overall the pooled data of the included studies showed an ED prevalence of 40.72% (95%CI: 31.80-50.29) in cancer patients, with prevalence of 28.60% (95%CI: 12.10%-53.83%) at time of diagnosis and 42.70% (95%CI: 32.97%-53.03%) after treatment, across cancer locations.

## Strengths and limitations

This systematic review and meta-analysis provides a comprehensive overview of evidence on the prevalence of ED in cancer survivors in general with studies using validated self-reported methods.

Limitations of our analysis include the inherent limitations from the included studies. Study populations were on average over 60 years old, which may have contributed to the prevalence as ED risks increase with age. Similar is the overrepresentation of cancer sites in the pelvic area. Again, due to the small number of primary studies that provide complete clinical and biological (e.g. serum testosterone or estradiol levels) features of the participants, we were not able to run some meta-regression analyses using well-known independent risk factors for ED (such as dyslipidemia, hypertension, diabetes mellitus and depression) as moderators of our findings. Lastly, the results pertaining to cancer survivors with multiple cancer sites need to be taken with caution given that there were only 3 primary studies that were included in the analysis.

*Comparison with existing literature*

Meta-analyses of studies reporting prevalence levels of ED in healthy men are rare and mostly focusing on samples of Asian men. These studies report that ED prevalence in individual studies has been reported from 2 to 82%, differing among age groups and how ED has been assessed. Generally, lowest reports have been found among younger men between 20 and 29 years old with 15.1% (12.2–18.1), while the highest have been found in the groups of 60 and over with 70.0% (62.3–77.7).29 Studies have noted that self-report leads to lower estimates than measuring by a standardized questionnaire. Overall pooled estimate for ED prevalence has been reported at 49.69% (95% CI = 39.29–60.10) for Chinese samples.30

Most studies included in our meta-analysis focused on cancers located in the pelvic region (prostate and rectum) and testis, where the effects would be expected to be strongest given the possible neurovascular damage associated with treatment. Androgen-deprivation therapy (ADT) which is used in prostate cancer management leads to ED in most men who had not dysfunction prior to therapy.31-33 Various chemotherapeutic agents may induce microangiopathy and vascular insufficiency in the *corpus cavernosum* of the penis as well as neurotoxicity that may result in ED.34 In a study of more than 260 men on platinum-based chemotherapy, 40% were reported to have ED on standardized questionnaires, which corresponds to the pooled data from our analysis.35 ED is also a common finding after radiation therapy for prostate cancer with varying incidence reported in studies depending on the dose, technique, associated treatments and time post-treatment, with brachytherapy showing lower rates of ED compared to external-beam radiation therapy in some studies.36-37

Surgical cancer treatment in the pelvic area may also lead to postoperative sexual dysfunction, depending both on the surgical techniques and methods used in assessing ED postoperatively. In one study more than 90% of patients who had radical prostatectomy reported lower scores on the IIEF-5 than before surgery,38 with an Italian based study reporting that reaching perioperative levels does not equal patient satisfaction, with little over one quarter of patients who reported preoperative scores reported being satisfied. Only men who achieved scores higher than 22, as measured by the IIEF, and returned to the same levels postoperatively were also satisfied with their sexual function.39 Similarly, 86% of men who had radical cystectomy were not able to achieve vaginal penetration and studies report between 10 and 50% of men having sexual dysfunction following colorectal surgery, where the proposed mechanism may lie in the injury to the hypogastric plexus. In testicular cancer survivors, a study measuring blood flow and erectile hemodynamics using duplex ultrasonography reported that 12 months after treatment there were no differences between men with or without hypogonadism, suggesting an hyperadrenergic mediated causes of ED.40

Sexual function may be influenced by systemic chemo- or radiation therapy, as well as by psychological factors such as depression, anxiety, low self-esteem or issues with body image, which are known conditions in all cancer patients and survivors, regardless of the primary cancer site.41-47 However, very few studies examine the effects of cancer sites outside of the pelvic area on the overall sexual function or ED, specifically, in men. A meta-analysis on sexual functioning in male lymphoma survivors reported prevalence of sexual dysfunction between 20 and 40%.48 Anecdotal evidence also suggests similar prevalence in patients with lung cancer. In fact, although this is the most prevalent cancer in men globally, there is still no research on sexual function in men lung cancer patients or survivors, as most of the focus is on short-term survival rather than post-treatment quality of life.49

## Implications for research and/or practice

Our analysis showed high prevalence of ED in cancer survivors at various points and across cancer types. As the aetiology of ED in cancer survivors is multimodal and it includes a variety of factors including psychological and physical ones. The results should improve the visibility of this issue and allow health care professionals to more easily identify cancer survivors under higher risk of ED. Moreover, it is important that clinicians be aware of the impact of ED on quality of life and mental health of cancer survivors, especially as sexuality and intimacy may reduce some of the psychosocial issues associated with receiving a cancer diagnosis.19,50 Various therapeutic modalities exist and health care providers should facilitate an open exchange with patients before cancer treatment and manage expectations. Here the primary care physicians are of great importance given their role in follow through during cancer care and beyond. As men are generally less prone to discuss sexual health problems in a clinical setting, clinicians should routinely and proactively ask about sexual health and recognize and acknowledge any concerns, which may increase the patient’s satisfaction and improve the doctor-patient relationship.51

**Funding:** None.

**Conflict of interest:** The authors received no third-party funding for this analysis and state no conflict of interest.

# References

1. Worldwide cancer data. Global cancer statistics for the most common cancers. Available at: <https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data> Accessed June 29, 2020.
2. Sadovsky R, Basson R, Krychman M, et al. Cancer and sexual problems. J Sex Med. 2010;7(1):349-373.
3. Virag R, Zwang G, Dermange H, et al. Vasculogenic impotence: a review of 92 cases with 54 surgical operations. Vasc Surg. 1981;15:9–17.
4. Kakehi Y. Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn J Clin Oncol 2003;33:1–5.
5. Gettman MT, Blute ML. Critical comparison of laparoscopic, robotic and open radical prostatectomy: Techniques, outcomes, and cost. Curr Urol Rep 2006;7:193–199.
6. Steineck G, Helgesen F, Adolfsson J, et al. Scandinavian prostatic cancer group study number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790–796.
7. Bacon CG, Giovannucci E, Testa M, et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001;166:1804–1810.
8. Zippe C, Nandipati K, Agarwal A, et al. Sexual dysfunction after pelvic surgery. Int J Impot Res 2006;18:1–18.
9. Johansson E, Steineck G, Holmberg L, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011;12(9):891-899.
10. Mohamed NE, Chaoprang Herrera P, Hudson S, et al. Muscle invasive bladder cancer: examining survivors’ burden and unmet needs. J Urol 2014;191(1):48-53.
11. Traa MJ, De Vries J, Roukema JA, et al. The sexual health care needs after colorectal cancer: the view of patients, partners, and health care professionals. Support Care Cancer. 2014;22(3):763-772.
12. Yau I, Vuong T, Garant A, et al. Risk of hypogonadism from scatter radiation during pelvic radiation in male patients with rectal cancer. Int J Radiat Oncol Biol Phys. 2009;74:1481–1486.
13. Modh RA, Mulhall JP, Gilbert SM. Sexual dysfunction after cystectomy and urinary diversion. Nat Rev Urol. 2014;11(8):445-453.
14. Tal R, Stember DS, Logmanieh N, et al. Erectile dysfunction in men treated for testicular cancer. BJU Int. 2014;113(6):907-910.
15. American Cancer Society. How Cancer Can Affect Erections. Available at: https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/fertility-and-sexual-side-effects/sexuality-for-men-with-cancer/erections-and-treatment.html Accessed June 29, 2020.
16. Lindau ST, Surawska H, Paice J, et al. Communication about sexuality and intimacy in couples affected by lung cancer and their clinical-care providers. Psychooncology. 2011;20(2):179-185.
17. Thygesen KH, Schjødt I, Jarden M. The impact of hematopoietic stem cell transplantation on sexuality: a systematic review of the literature. Bone Marrow Transplant. 2012;47(5):716-724.
18. Nelson CJ, Mulhall JP, Roth AJ. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J Sex Med. 2011;8(2):560-566.
19. Hordern AJ, Currow DC. A patient-centered approach to sexuality in the face of life-limiting illness. Med J Aust 2003;179(suppl):S8–S11.
20. Wimberly SR, Carver CS, Laurenceu JP, et al. Perceived partner reactions to diagnosis and treatment of breast cancer: Impact on psychosocial and psychosexual adjustment. J Consult Clin Psychol 2005;73:300–311.
21. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2019 Available from: http://www.R-project.org/
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986;7:177–188.
23. Sterne JAC, Egger M. Regression methods to detect publication and other bias in meta-analysis. In: Rothstein HR, Sutton AJ, Borenstein M, editors. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. Chichester, UK: Wiley; 2005. p. 99–110.
24. Duval S, Tweedie RL. Trim and fill: A simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–463.
25. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br. Med. J. 2003;327:557–560.
26. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
27. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available at: <http://wwwohrica/programs/clinical_epidemiology/oxfordasp>. Accessed June 29, 2020.
28. Luchini C, Brendon S, Solmi M, et al. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. World J Meta-Anal. 2017;5:80-84.
29. Cheng J, Ng E, Chen R, et al. Prevalence of erectile dysfunction in Asian populations: a meta-analysis. Int J Impot Res 2007;19:229–244.
30. Wang W, Fan J, Huang G, et al. Meta-Analysis of Prevalence of Erectile Dysfunction in Mainland China: Evidence Based on Epidemiological Surveys. Sex Med. 2017;5(1):e19-e30.
31. Mazzola CR, Mulhall JP. Impact of androgen deprivation therapy on sexual function. Asian J Androl. 2012;14(2):198-203.
32. Donovan KA, Gonzalez BD, Nelson AM, et al. Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison. Psychooncology. 2018;27(1):316-324.
33. White ID, Wilson J, Aslet P, et al. Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer. Int J Clin Pract. 2015;69(1):106-123.
34. Chatterjee R, Andrews HO, McGarrigle HH, et al. Cavernosal arterial insufficiency is a major component of erectile dysfunction in some recipients of high-dose chemotherapy/chemo-radiotherapy for haematological malignancies. Bone marrow transplant 2000;25(11):1185-1189.
35. Wiechno P, Demkow T, Kubiak K, et al. The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. Eur Urol. 2007; 52(5):1448-1455.
36. Demanes DJ, Ghilezan MI. High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy. 2014;13(6):529-541.
37. Putora PM, Engeler D, Haile SR, et al. Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients. Strahlenther Onkol. 2016;192(3):182-189.
38. Fode M, Frey A, Jakobsen H, et al. Erectile function after radical prostatectomy: Do patients return to baseline? Scand J Urol. 2016;50(3):160-163.
39. Rossi MS, Moschini M, Bianchi M, et al. Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction? J Sex Med. 2016;13(4):669-678.
40. Tal R, Stember DS, Logmanieh N, et al. Erectile dysfunction in men treated for testicular cancer. BJU Int. 2014;113(6):907-910.
41. Schover LR, van der Kaaij M, van Dorst E, et al. Sexual dysfunction and infertility as late effects of cancer treatment. EJC Suppl. 2014;12(1):41-53.
42. Voznesensky M, Annam K, Kreder KJ. Understanding and Managing Erectile Dysfunction in Patients Treated for Cancer [published correction appears in J Oncol Pract. 2016;12(6):596]. J Oncol Pract. 2016;12(4):297-304.
43. Nelson CJ, Mulhall JP, Roth AJ. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J Sex Med. 2011;8(2):560-566.
44. Roth AJ, Weinberger MI, Nelson CJ. Prostate cancer: psychosocial implications and management. Future Oncol. 2008;4(4):561-568.
45. Moore TM, Strauss JL, Herman S, et al. Erectile dysfunction in early, middle, and late adulthood: symptom patterns and psychosocial correlates. J Sex Marital Ther. 2003;29(5):381-399.
46. Rossen P, Pedersen AF, Zachariae R, et al. Sexuality and body image in long‐term survivors of testicular cancer. Eur J Cancer 2012;48(4):571–578.
47. Fingeret MC, Teo I, Epner DE. Managing body image difficulties of adult cancer patients: lessons from available research. Cancer. 2014;120(5):633-641.
48. Arden-Close E, Eiser C, Pacey A. Sexual Functioning in Male Survivors of Lymphoma: A Systematic Review (CME). J Sex Med 2011;8(7):1833–1840.
49. Furlow B. Sexual dysfunction in patients with lung disease. Lancet Respir Med. 2014;2(6):439.
50. Wimberly SR, Carver CS, Laurenceu JP, et al. Perceived partner reactions to diagnosis and treatment of breast cancer: Impact on psychosocial and psychosexual adjustment. J Consult Clin Psychol 2005;73:300–311.
51. Sadovsky R. The role of the primary care clinician in the management of erectile dysfunction. Rev Urol. 2002;4(Suppl 3):S54-S63.

# Tables and Figures

**Table 1:** Study Count and Pooled Prevalence of ED across Three Stages

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Healthy Control | At Diagnosis | After Treatment | Total |
| Study Count | 3 | 5 | 35 | 43 |
| Pooled number of patients with ED | 250 | 782 | 2794 | 3826 |
| Pooled sample size | 1240 | 2403 | 9505 | 13148 |
| Pooled Prevalence (95% CI) | 0.1370  (0.0394; 0.3808) | 0.2861  (0.1229; 0.5340) | 0.4269\*  (0.3311; 0.5286) |  |

\* indicates that the ED prevalence among cancer patients after treatment is significantly different from that of healthy control at level 0.05 (p = 0.0322; this can also be seen by the fact that the point estimate of ED prevalence for healthy control, 0.1370, is not included in the 95% C.I. of ED prevalence for cancer patients after treatment)

**Table 2:** Study Count of the 10 Possible Predictors for the ED Prevalence and P-value for the Uni-predictor (or Smallest P-value for the Uni-predictor Dummy Variables) in the Univariate MA Regression Analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Predictor** | **Study Count** | **Coef. Est.** | **95% C.I.** | **P-value** |
| Stage | 40 | 0.6210 | (-0.5253, 1.7673) | 0.2883 |
| Continent | 40 | 1.2655 | (-0.3051, 2.8362) | 0.1143 |
| Mean age | 40 | 0.0503 | (0.0243, 0.0762) | 0.0002\* |
| Range of age | 40 | 0.0057 | (-0.0210, 0.0325) | 0.6739 |
| Assessment method of ED | 40 | 1.5236 | (-0.1845, 3.2316) | 0.0804 |
| Cancer site | 40 | -1.8135 | (-2.5841, -1.0429) | <.0001  \*\*\* |
| Standard deviation of age | 17 | -0.0078 | (-0.0733, 0.0576) | 0.8144 |
| Proportion of patients underwent radiotherapy | 15 | 1.0584 | (-1.0225, 3.1393) | 0.3188 |
| Proportion of patients with diabetes | 12 | -3.6361 | (-19.1360, 11.8639) | 0.6457 |
| Proportion of patients underwent chemotherapy | 12 | 0.1348 | (-1.9925, 2.2621) | 0.9012 |

Note: significance code controlling for type I error rate less than 0.05 and greater than 0.01: ‘\*’; significance code controlling for type I error rate less than 0.0001: ‘\*\*\*’.


**Table 3:** A prediction model for the highly heterogeneous ED prevalence

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Regression Coefficients** | **Estimate** | **Standard error** | **z** | **P-value** | **Adjusted P-value** |
| Intercept | -0.5380 | 0.2720 | -1.9778 | 0.0479 | 0.0659 |
| Stage: After Treatment | 0.9092 | 0.3279 | 2.7726 | 0.0056 | 0.0204 \* |
| Cancer site: Colon | -1.4697 | 0.6089 | -2.4136 | 0.0158 | 0.0434 \* |
| Cancer site: Colorectal | 0.9628 | 0.4856 | 1.9830 | 0.0474 | 0.0744 |
| Cancer site: Haematologic | -0.0742 | 0.4759 | -0.1560 | 0.8761 | 0.9637 |
| Cancer site: Lymphoma | -1.3744 | 0.6165 | -2.2293 | 0.0258 | 0.0473 \* |
| Cancer site: Multiple | -2.2625 | 0.4643 | -4.8726 | <.0001 | <.0001 \*\*\* |
| Cancer site: Penis | -1.7574 | 0.7535 | -2.3324 | 0.0197 | 0.0433 \* |
| Cancer site: Anus | 0.1397 | 0.9449 | 0.1478 | 0.8825 | 0.8825 |
| Cancer site: Rectum | -0.3761 | 0.2919 | -1.2888 | 0.1975 | 0.2414 |
| Cancer site: Testis | -2.0001 | 0.3148 | -6.3533 | <.0001 | <.0001 \*\*\* |


Note: significance code controlling for false discovery rate (FDR) less than 0.05 and greater than 0.01: ‘\*’; significance code controlling for false discovery rate (FDR) less than 0.0001: ‘\*\*\*’.

**Table 4:** Back-transformed estimated prevalence values of ED with 95% C.I. for studies with patients of different cancers at the two stages by the predictive MA regression model


|  |  |  |
| --- | --- | --- |
| Cancer site | At diagnosis | After treatment |
| Prostate cancer | 59.2% (48.7%, 68.9%) | 78.3% (58.2%, 90.3%) |
| Colon cancer | 25.0% (9.8%, 50.4%) | 45.3% (18.6%, 75.0%) |
| Colorectal cancer | 79.1% (61.8%, 89.9%) | 90.4% (76.4%, 96.5%) |
| Haematologic cancer | 57.4% (37.0%, 75.5%) | 77.0% (53.9%, 90.5%) |
| Lymphoma cancer | 26.8% (10.6%, 53.2%) | 47.6% (19.9%, 77.0%) |
| Multiple cancer | 13.1% (6.3% , 25.2%) | 27.2% (11.8%, 51.2%) |
| Penis cancer | 20.0% (5.7% , 50.7%) | 38.3% (11.6%, 74.6%) |
| Anus cancer | 62.5% (21.6%, 91.0%) | 80.5% (37.9%, 96.6%) |
| Rectum cancer | 49.9% (40.4%, 59.4%) | 71.2% (53.9%, 83.9%) |
| Testis cancer | 16.4% (10.7%, 24.3%) | 32.7% (16.8%, 53.9%) |



**Figure 1:** Comparisons of prevalence of ED among cancer patients and healthy control



**Figure 2:** Funnel plot

****

**Figure 3:** Prevalence of ED among cancer patients